ALPPL2 Biomarker Panel for Estrogen-Induced Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for endometrial cancer, such as stathmin and CA-125, lack specificity and sensitivity for early detection and prognosis, particularly in advanced stages, necessitating the identification of improved estrogen-responsive biomarkers for timely diagnosis and treatment.
Innovation Solution
The method involves determining the level of expression of placental-like alkaline phosphatase 2 (ALPPL2) in biological samples, comparing it to reference samples, and using statistical analyses to indicate the presence, risk, or prognosis of estrogen-induced cancers like endometrial and ovarian cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing biomarkers (stathmin, CA-125) are used for endometrial cancer detection, then the diagnostic process is simple and cost-effective, but the sensitivity and specificity for early detection and prognosis are insufficient
Solution Approach 1:
The patent changes the biomarker parameter from traditional markers (CA-125, stathmin) to a new panel including GATA6, ALPPL2, and other estrogen-responsive genes. This parameter change improves diagnostic sensitivity and specificity for early-stage endometrial cancer while maintaining assay feasibility through standardized molecular biology techniques
Solution Approach 2:
The patent employs a composite biomarker panel combining multiple genes (GATA6, ALPPL2, CYP19A1, ESR1, etc.) rather than relying on a single marker. This composite approach synergistically improves diagnostic accuracy and prognostic value, addressing the limitations of individual biomarkers while providing comprehensive cancer detection and monitoring capabilities
2Reliability
If early detection of endometrial cancer is achieved, then patient survival rate improves significantly, but current biomarkers lack the ability to detect early stage cancer
Solution Approach 1:
The patent identifies and measures estrogen-responsive gene expression parameters (GATA6, ALPPL2, CYP19A1, ESR1) that are upregulated in early-stage endometrial cancer. This parameter change enables detection of molecular changes before anatomical changes occur, allowing early intervention and improving survival outcomes
Solution Approach 2:
The biomarker panel detects molecular signatures of estrogen-driven carcinogenesis before clinical symptoms or anatomical changes manifest. This preliminary detection capability allows for pre-symptomatic diagnosis and early treatment intervention, directly improving patient survival rates by catching cancer at treatable stages
3Measurement precision
If a comprehensive biomarker panel is used to improve diagnostic accuracy, then detection sensitivity improves, but the complexity and cost of the diagnostic process increases
Solution Approach 1:
The patent designs a multi-functional biomarker panel that simultaneously performs multiple diagnostic functions: early cancer detection, prognosis prediction, and treatment response monitoring. The same panel of estrogen-responsive genes serves all these purposes, improving comprehensive diagnostic capability without proportionally increasing complexity
Solution Approach 2:
The patent focuses on a specific set of estrogen-responsive genes (GATA6, ALPPL2, CYP19A1, ESR1, PGR, AR) that can be measured using standardized molecular biology techniques. This targeted parameter selection improves detection sensitivity while maintaining assay feasibility through established laboratory methods, avoiding the need for complex or proprietary technologies
Data Source
AI summary
Provided herein are methods for detecting an estrogen-induced cancer in a subject, for identifying a subject at risk of developing an estrogen-induced cancer and for determining or predicting prognosis for a subject with an estrogen-induced cancer. The methods of the disclosure comprise determining the level of expression of ALPPL2 in a biological sample, typically a blood sample, obtained from a subject.